[1] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol,2019,71(1): 212-221. [2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):177-186. [3] Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol,2017,66(5): 1022-1030. [4] Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology,2020,71(3): 808-819. [5] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1): 202-209. [6] Lei X, Seldin MM, Little HC, et al. C1q/TNF-related protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J Biol Chem, 2017,292(36): 14836-14850. [7] Yao Y, Miao X, Zhu D, et al. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Endocrine,2019,65(2): 227-237. [8] Li L, Liu DW, Yan HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev,2016,17(6): 510-519. [9] Chen Y, Wang X, Wang J, et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer,2012,48(14): 2137-2145. [10] Vilar GE, Martinez PY, Calzadilla BL, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology,2015,149(2): 367-378. [11] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism,2016,65(8): 1038-1048. [12] Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism,2018,79: 64-76. [13] Wijarnpreecha K, Panjawatanan P, Lekuthai N, et al. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. Liver Int,2017,37(6): 906-918. [14] Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: A Meta-Analysis. Acta Med Indones,2017,49(2): 136-147. [15] Bugianesi E, Moscatiello S, Ciaravella MF, et al. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des,2010,16(17): 1941-1951. [16] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated Meta-analysis of 501 022 adult individuals. Gut,2021,70(5): 962-969. [17] Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology,2020,71(3): 907-916. [18] Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore),2017,96(39): e8179. [19] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议(2019年修订版).实用肝脏病杂志,2019,22(6):787-792. [20] Qu Y, Song YY, Chen CW, et al. Diagnostic performance of fibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol,2021,12(4): e00323. |